drugset
drugset / Trial / NCT03004768

Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants

NCT03004768 ↗

Phase 1 Completed 6 enrolled Bristol-Myers Squibb Covance · collab
NaSingle-groupOpen-labelTreatment

Summary

An oral dose in healthy subjects to obtain information about the absorption, metabolism, and excretion (AME) of BMS-986165

Timeline

Start
2017-01-26
Primary completion
2017-02-27
Completion
2017-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule 24 mg Oral

Indications

psoriasis